Glucagon-like peptides

Diabetes

Volumn 47, Issue 2, 1998, Pages 159-169

  Drucker, Daniel J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GROWTH FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; ENDOCRINE CELL; FLUID INTAKE; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; GLYCOGEN SYNTHESIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE CELL; INTESTINE MUCOSA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; REGENERATION; REVIEW; STOMACH EMPTYING;

EID: 0031936954     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.47.2.159     Document Type: Review

References (167)

1. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y: Plasma insulin response to oral and intravenous glucose administration. J Clin Invest 24:1076-1082, 1964
2. Perley MJ, Kipnis DM: Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46:1954-1962, 1967
3. Creutzfeldt W, Ebert R: New developments in the incretin concept today. Diabetologia 28:565-573, 1985
4. Fehmann H-C, Goke R, Goke B: Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent releasing polypeptide. Endocrine Rev 16:390-410, 1995
5. Bell GI, Santerre RF, Mullenbach GT: Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716-718, 1983
6. Lopez LC, Frazier ML, Su CJ, Kumar A, Saunders GF: Mammalian pancreatic preproglucagon contains three glucagon-related peptides. Proc Natl Acad Sci USA 80:5485-5489, 1983
7. Heinrich G, Gros P, Lund PK, Bentley RC, Habener JF: Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid Endocrinology 115:2176-2181, 1984
8. Schmidt WE, Siegel EG, Creutzfeldt W: Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28:704-707, 1985
9. Mojsov S, Weir GC, Habener JF: Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616-619, 1987
10. Holst JJ, Orskov C, Nielsen OV, Schwartz TW: Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174, 1987
11. Kreymann B, Ghatei MA, Williams G, Bloom SR: Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet ii:1300-1304, 1987
12. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438, 1987
13. Thorens B, Waeber G: Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM. Diabetes 42:1219-1225, 1993
14. Holst JJ: Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107:1848-1855, 1994
15. Drucker DJ: Intestinal growth factors. Am J Physiol 36:G3-G6, 1997
16. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF: Preproglucagon gene egression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol Chem 261:11880-11889, 1986
17. Irwin DM, Wong J: Trout and chicken proglucagon: Alternative splicing generates mRNA transcripts encoding glucagon-like peptide 2. Mol Endocrinol 9:267-277, 1995
18. Chen YE, Drucker DJ: Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin-4 in the lizard. J Biol Chem 272:4108-4115, 1997
19. Efrat S, Teitelman G, Anwar M, Ruggiero D, Hanahan D: Glucagon gene regulatory region directs oncoprotein expression to neurons and pancreatic alpha cells. Neuron 1:605-613, 1988
20. Lee YC, Asa SL, Drucker DJ: Glucagon gene 5′-flanking sequences direct expression of SV40 large T antigen to the intestine producing carcinoma of the large bowel in transgenic mice. J Biol Chem 267:10705-10708, 1992
21. Jin T, Drucker DJ: The proglucagon gene upstream enhancer contains positive and negative domains important for tissue-specific proglucagon gene transcription. Mol Endocrinol 9:1306-1320, 1995
22. Jin T, Drucker DJ: Activation of proglucagon gene transcription through a novel promoter element by the caudal-related homeodomain protein cdx-2/3. Mol Cell Biol 16:19-28, 1996
23. Laser B, Meda P, Constant I, Philippe J: The caudal-related homeodomain protein cdx-2/3 regulates glucagon gene expression in islet cells. J Biol Chem 271:28984-28994, 1996
24. Rothenberg ME, Eilertson CD, Klein K, Zhou Y, Lindberg I, McDonald JK, Mackin RB, Noe BD: Processing of mouse proglucagon by recombinant prohormone convertase 1 and immunopurified prohormone convertase 2 in vitro. J Biol Chem 270:10136-10146, 1995
25. Dhanvantari S, Seidah NG, Brubaker PL: Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 10:342-355, 1996
26. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535-539, 1994
27. Orskov C, Wettergren A, Holst JJ: Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661, 1993
28. Reimer RA, McBurney MI: Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology 137:3948-3956, 1996
29. Hoyt EC, Lund PK, Winesett DE, Fuller CR, Ghatei MA, Bloom SR, Ulshen MR: Effects of fasting, refeeding and intraluminal triglyceride on proglucagon expression in jejunum and ileum. Diabetes 45:434-439, 1996
30. Roberge JN, Gronau KA, Brubaker PL: Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology 137:2383-2388, 1996
31. Herrmann-Rinke C, Voge A, Hess M, Goke B: Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J Endocrinol 147:25-31, 1995
32. Dumoulin V, Dakka T, Plaisancie P, Chayvialle J-A, Cuber J-C: Regulation of glucagon-like peptide-1(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology 136:5182-5188, 1995
33. Plaisancie P, Bernard C, Chayvialle J-A, Cuber J-C: Regulation of glucagon-like peptide-1(7-36)amide, peptide YY, and neurotensin secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon. Endocrinology 135:2398-2403, 1994
34. Herrmann-Rinke C, Horsch D, McGregor GP, Goke B: Galanin is a potent inhibitor of glucagon-like peptide-1 secretion from rat ileum. Peptides 17:571-576, 1996
35. Plaisancié P, Dumoulin V, Chayvialle J-A, Cuber J-C: Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon. J Endocrinol 145:521-526, 1995
36. Herrmann C, Goke R, Richter G, Fehmann H-C, Arnold R, Goke B: Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digest 56:117-126, 1995
37. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V: Glucagon-like peptide-1(7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 138:159-166, 1993
38. Orskov C, Wettergren A, Holst JJ: Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31:665-670, 1996
39. Balks HJ, Holst JJ, von zur Muhlen A, Brabant G: Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 82:786-790, 1997
40. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835, 1993
41. Kieffer TJ, McIntosh CHS, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596, 1995
42. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin Endocrinol Metab 80:952-957, 1995
43. Knudsen LB, Pridal L: Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36)amide after in vivo administration to dogs and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318:429-135, 1996
44. Ruiz-Grande C, Alarcón C, Alcántara A, Castilla C, López Novoa JM, Villanueva-Peñacarrillo ML, Valverde I: Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 25:612-616, 1993
45. Thorens B: Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89:8641-8645, 1992
46. Thorens B, Porret A, Bühler L, Deng S-P, Morel P, Widmann C: Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42:1678-1682, 1993
47. Dillon JS, Tanizawa Y, Wheeler MB, Leng X-H, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA, Boyd AE III: Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology 133:1907-1910, 1993
48. Stoffel M, Espinosa R III, Le Beau MM, Bell GI: Human glucagon-like peptide-1 receptor gene: localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6. Diabetes 42:1215-1218, 1993
49. Zhang Y, Cook JTE, Hattersley AT, Firth R, Saker PJ, Warren-Perry M, Stoffel M, Turner RC: Non-linkage of the glucagon-like peptide-1 receptor gene with maturity onset diabetes of the young. Diabetologia 37:721-724, 1994
50. Wheeler MB, Lu M, Dillon JS, Leng X-H, Chen C, Boyd AE III: Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenyl cyclase and phospholipase-C. Endocrinology 133:57-62, 1993
51. Wei Y, Mojsov S: Tissue-specific expression of the human receptor for glucagon-like peptide 1: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358:219-224, 1995
52. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor. Endocrinology 137:2968-2978, 1996
53. Mérida E, Delgado E, Molina LM, Villanueva-Peñacarrillo ML, Valverde I: Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J. Clin Endocrinol Metab 77:1654-1657, 1993
54. Delgado E, Luque MA, Alcántara A, Trapote MA, Clemente F, Galera C, Valverde I, Villanueva-Peñacarrillo ML: Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 16:225-229, 1995
55. Holz GG, Kühtreiber WM, Habener JF: Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361:362-365, 1993
56. Lu M, Wheeler MB, Leng X-H, Boyd AE III: The role of the free cytoplasmic calcium level in β-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). Endocrinology 132:94-100, 1993
57. Gromada J, Dissing S, Bokvist K, Renström E, Frokjær-Jensen J, Wulff BS, Rorsman P: Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting βTC3-cells by enhancement of intracellular calcium mobilization. Diabetes 44:767-774, 1995
58. 2+-signaling pathway in pancreatic β-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270:17749-17757, 1995
59. Widmann C, Dolci W, Thorens B: Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Mot Endocrinol 10:62-75, 1996
60. Gromada J, Dissing S, Rorsman P: Desensitization of the glucagon-like peptide 1 receptors in insulin-secreting βTC3 cells: role of PKA-independent mechanisms. Br J Pharmacol 118:769-775, 1996
61. Widmann C, Dolci W, Thorens B: Heterologous desensitization of the glucagon-like peptide-1 receptor by phorbol esters requires phosphorylation of the cytoplasmic tail at four different sites. J Biol Chem 271:19957-19963, 1996
62. Fehmann H-C, Habener JF: Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinology 130:159-166, 1992
63. Wang YH, Egan JM, Raygada M, Nadiv O, Roth J, Montrose-Rafizadeh C: Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 136:4910-4917, 1995
64. Gutniak MK, Juntti-Berggren L, Hellstrom PM, Guenifi A, Holst JJ, Efendic S: Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 19:857-863, 1996
65. Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose-Rafizadeh C, Elahi D, Egan JM: Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 99:2883-2889, 1997
66. Kawai K, Suzuki S, Ohashi S, Mukai H, Ohmori H, Murayama Y, Yamashita K: Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology 124:1768-1773, 1989
67. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S: Glucagonostatic and insulinotropic action of glucagon-like peptide I-(7-36)-amide. Diabetes 38:902-905, 1989
68. Freyse E-J, Becher T, El-Hag O, Knospe S, Goke B, Fischer U: Blood glucose lowering and glucagonostatic effects of glucagon-like peptide I in insulin-deprived diabetic dogs. Diabetes 46:824-828, 1997
69. Heller RS, Kieffer TJ, Habener JF: Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46:785-791, 1997
70. D'alessio DA, Fujimoto WY, Ensinck JW: Effects of glucagonlike peptide I(7-36) on release of insulin, glucagon, and somatostatin by rat pancreatic islet cell monolayer cultures. Diabetes 38:1534-1538, 1989
71. Matsumura T, Itoh H, Watanabe N, Oda Y, Tanaka M, Namba M, Kono N, Matsuyama T, Komatsu R, Matsuzawa Y: Glucagonlike peptide-1(7-36) amide suppresses glucagon secretion and decreases cyclic AMP concentration in cultured In-R1-G9 cells. Biochem Biophys Res Commun 186:503-508, 1992
72. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
73. Schmidtler J, Dehne K, Allescher H-D, Schusdziarra V, Classen M, Holst JJ, Polack A, Schepp W: Rat parietal cell receptors for GLP-1-(7-36) amide: Northern blot, cross-linking, and radioligand binding. Am J Physiol 267:G423-G432, 1994
74. Barragan JM, Rodriguez RE, Blazquez E: Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36 amide) in rats. Am J Physiol 266:E459-E466, 1994
75. Kanse SM, Kreymann B, Ghatei MA, Bloom SR: Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung. FEBS Lett 241:209-212, 1988
76. Richter G, Göke R, Göke B, Schmidt H, Arnold R: Characterization of glucagon-like peptide-I(7-36)amide receptors of rat lung membranes by covalent cross-linking. FEBS Lett 280:247-250, 1991
77. Richter G, Feddersen O, Wagner U, Barth P, Göke R, Göke B: GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 265:L374-L381, 1993
78. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, Perea A, Villanueva-Penacarillo ML: Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349:313-316, 1994
79. Villanueva-Peñacarrillo ML, Delgado E, Trapote MA, Alcántara A, Clemente F, Luque MA, Perea A, Valverde I: Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 146:183-189, 1995
80. Conlon JM, Youson JH, Mommsen TP: Structure and biological activity of glucagon and glucagon-like peptide from a primitive bony fish, the bowfin (Amia calva). Biochem 7295:857-861, 1993
81. Nakagawa Y, Kawai K, Suzuki H, Ohashi S, Yamashita K: Glucagon-like peptide-1(7-36) amide and glycogen synthesis in the liver. Diabetologia. 39:1241-1242, 1996
82. Villanueva-Peñacarrillo ML, Alcántara AI, Clemente F, Delgado E, Valverde I: Potent glycogenic effect of GLP-1(7-36) amide in rat skeletal muscle. Diabetologia 37:1163-1166, 1994
83. Morales M, Lopez-Delgado MI, Alcantara A, Luque MA, Clemente F, Marquez L, Puente J, Vinambres C, Malaisse WJ, Villanueva-Penacarrillo ML, Valverde I: Preserved GLP-1 effects on glycogen synthase a activity and glucose metabolism in isolated hepatocytes and skeletal muscle from diabetic rats. Diabetes 46:1264-1269, 1997
84. Furnsinn C, Ebner K, Waldhausl W: Failure of GLP-1 (7-36) amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38:864-867, 1995
85. Valverde I, Merida E, Delgado E, Trapote MA, Villanueva-Penacarillo ML: Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue. Endocrinology 132:75-79, 1993
86. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J: Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135:2070-2075, 1994
87. Miki H, Namba M, Nishimura T, Mineo I, Matsumura T, Miyagawa J, Nakajima H, Kuwajima M, Hanafusa T, Matsuzawa Y: Glucagon-like peptide-1(7-36) amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Biochim Biophys Acta 1312:132-136, 1996
88. Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams LG: Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol 172:275-283, 1997
89. Shimizu I, Hirota M, Ohboshi C, Shima K: Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121:1076-1082, 1987
90. Uttenthal LO, Toledano A, Blazquez E: Autoradiographic localization of receptors for glucagon-like peptide-1(7-36) amide in rat brain. Neuropeptides 21:143-146, 1992
91. Kreymann B, Ghatei MA, Burnet P, Williams G, Kanse S, Diani AR, Bloom SR: Characterization of glucagon-like peptide-1-(7-36)amide in the hypothalamus. Brain Res 502:325-331, 1989
92. Drucker DJ, Asa S: Glucagon gene expression in vertebrate brain. J Biol Chem 263:13475-13478, 1988
93. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C: Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77:257-270, 1997
94. Alvarez E, Roncero I, Chowen JA, Thorens B, Blazquez E: Expression of the glucagon-like peptide-1 receptor gene in rat brain. J Neurochem 66:920-927, 1996
95. Campos RV, Lee YC, Drucker DJ: Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134:2156-2164, 1994
96. Beak SA, Small CJ, Ilovaiskaia I, Hurley JD, Ghatei MA, Bloom SR, Smith DM: Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. Endocrinology 137:4130-4138, 1996
97. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP: Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary. Neuroendocrinology 62:130-134, 1995
98. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A: Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271:E808-E813, 1996
99. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72, 1996
100. Van Dijk G, Thiele TE, Donahey JCK, Campfield LA, Smith FJ, Burn P, Bernstein IL, Woods SC, Seeley RJ: Central infusions of leptin and GLP-1(7-36) amide differentially stimulate c-FLI in the rat brain. Am J Physiol 271:R1096-R1100, 1996
101. Thiele TE, Van Dijk G, Campfield LA, Smith FJ, Burn P, Woods SC, Bernstein H, Seeley RJ: Central infusion of GLP-1, but not leptin, produces conditioned taste aversion in rats. Am J Physiol 272:R726-R730, 1997
102. Navarro M, Rodriguez de Fonseca F, Alvarez E, Chowen JA, Zueco JA, Gomez R, Eng J, Blazquez E: Colocalization of glucagon-like peptide-1(GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67:1982-1991, 1996
103. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh SP: Central administration of GLP-1 (7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856, 1996
104. Göke R, Fehmann H-C, Linn T, Schmidt H, Krause M, Eng J, Göke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268:19650-19655, 1993
105. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR: Glucagon-like peptide 1 is a physiological incretin in rat. J Clin Invest 95:417-421, 1995
106. Kolligs F, Fehmann H-C, Göke R, Göke B: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44:16-19, 1995
107. D'alessio DA, Vogel R, Prigeon R, Laschansky E, Koerker D, Eng J, Ensinck JW: Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-138, 1996
108. Barragan JM, Rodriguez RE, Eng J, Blazquez E, Defize LHK: Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept 67:63-68, 1996
109. Alcantara AI, Morales M, Delgado E, Lopez-Delgado MI, Clemente F, Luque MA, Malaisse WJ, Valverde I: Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36) amide effects in liver and muscle. Arch Biochem Biophys 341:1-7, 1997
110. Wheeler MB, Gelling RW, McIntosh CHS, Georgiou J, Brown JC, Pederson RA: Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signalling properties. Endocrinology 136:4629-4639, 1995
111. Gremlich S, Porret A, Hani EH, Cherif D, Vionnet D, Froguel P, Thorens B: Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44:1202-1208, 1995
112. Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J: High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 272:21201-21207, 1997
113. Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat Med 2:1254-1258, 1996
114. Scrocchi LA, Brown TJ, Drucker DJ: Leptin sensitivity in nonobese glucagon-like peptide I receptor -/- mice. Diabetes 46:2029-2034, 1997
115. Erickson JC, Clegg KE, Palmiter RD: Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381:415-418, 1996
116. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. AT Engl J Med 326:1316-1322, 1992
117. Ritzel R, Orskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers: dose-response relationships. Diabetologia 38:720-725, 1995
118. Hvidberg A, Nielsen MT, Hilsted J, Orskov C, Holst JJ: Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 43:104-108, 1994
119. Toft-Nielsen M, Madsbad S, Holst JJ: The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556, 1996
120. D'alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J. Clin Invest 93:2263-2266, 1994
121. D'alessio DA, Prigeon RL, Ensinck JW: Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: a physiological role of glucagon-like peptide I. Diabetes 44:1433-1437, 1995
122. Orskov L, Holst JJ, Moller J, Orskov C, Moller N, Alberti KG, Schmitz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232, 1996
123. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B: Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buctial tablet. Diabetes Care 19:843-848, 1996
124. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
125. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36)amide in type 2 (non-insulin dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332, 1996
126. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
127. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1(7-36) amide in patients with NIDDM. Diabetes 45:1524-1530, 1996
128. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM Diabetes Care 17:1039-1044, 1994
129. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997
130. Rachman J, Barrow BA, Levy JC, Turner RC: Near normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211, 1997
131. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1[7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553, 1996
132. Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, Efendic S: The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 19:1200-1206, 1996
133. Todd JF, Wilding JP, Edwards CM, Ghatei MA, Bloom SR: Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:533-536, 1997
134. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ: Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44:626-630, 1995
135. Dupre J, Behme MT, Hramiak IM, McDonald TJ: Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM. Diabetes Care 20:381-384, 1997
136. Creutzfeld WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type 1 diabetic patients. Diabetes Care 19:580-586, 1996
137. Eng J, Andrews PC, Kleinman WA, Singh L, Raufman JP: Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J Biol Chem 265:20259-20262, 1990
138. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin-4, an exendin 3 analogue from Heloderma suspectum venom. J Biol Chem 267:7402-7405, 1992
139. Raufman J-P: Bioactive peptides from lizard venoms. Regul Pept 61:1-18, 1996
140. Raufman J-P, Singh L, Singh G, Eng J: Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas: identification of a mammalian homologue of the reptilian peptide exendin-4. J Biol Chem 267:21432-21437, 1992
141. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Rüdiger G, Burkhard G, Thole H, Zimmermann B, Voigt K Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58:149-156, 1995
142. Irwin DM, Satkunarajah M, Wen Y, Brubaker PL, Pederson RA, Wheeler MB: The Xenopus proglucagon gene encodes novel GLP-1-like peptides with insulinotropic properties. Proc Natl Acad Sci USA 94:7915-7920, 1997
143. Gefel D, Hendrick GK, Mojsov S, Habener J, Weir GC: Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3′,5′-monophosphate formation. Endocrinology 126:2164-2168, 1990
144. Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O: Structure-activity studies of glucagon-like peptide-1. J Biol Chem 269:6275-6278, 1994
145. Hjorth SA, Adelhorst K, Pedersen BB, Kirk O, Schwartz TW: Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J Biol Chem 269:30121-30124, 1994
146. Gallwitz B, Witt M, Morys-Wortmann C, Folsch UR, Schmidt WE: GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1. Regul Pept 63:17-22, 1996
147. Gallwitz B, Witt M, Paetzold G, Morys-Wortmann C, Zimmermann B, Eckart K, Fölsch UR, Schmidt WE: Structure/activity characterization of glucagon-like peptide-1. Eur J Biochem 225:1151-1156, 1994
148. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC: Exon duplication and divergence in the human preproglucagon gene. Nature 304:368-371, 1983
149. Lund PK, Goodman RH, Dee PC, Habener JF: Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem, Proc Natl Acad Sci USA 79:345-349, 1982
150. Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH: Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 12:773-782, 1971
151. Stevens FM, Flanagan RW, O'Gorman D, Buchanan KD: Glucagonoma syndrome demonstrating giant duodenal villi. Gut 25:784-791, 1984
152. Bloom SR, Polak JM: The hormonal pattern of intestinal adaptation. Scand J Gastroenterol 17:93-103, 1988
153. Sagor GR, Ghatei MA, Al-Mukhtar MYT, Wright NA, Bloom SR: Evidence for a humoral mechanism after small intestinal resection. Gastroenterology 84:902-906, 1983
154. Taylor RG, Verity K, Fuller PJ: Ileal glucagon gene expression: ontogeny and response to massive small bowel resection. Gastroenterology 99:724-729, 1990
155. Fuller PJ, Beveridge DJ, Taylor RG: Deal proglucagon gene expression in the rat: characterization in intestinal adaptation using in situ hybridization. Gastroenterology 104:459-466, 1993
156. Ehrlich P, Tucker D, Asa SL, Brubaker PL, Drucker DJ: Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors. Am J Physiol 267:E662-E671, 1994
157. Tsai C-H, Hill M, Asa SL, Brubaker PL, Drucker DJ: Intestinal growth-promoting properties of glucagon-like peptide 2 in mice. Am J Physiol 273:E77-E84, 1997
158. Drucker DJ, Ehrlich P, Asa SL, Brubaker PL: Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93:7911-7916, 1996
159. Drucker DJ, Deforest L, Brubaker PL: Intestinal response to growth factors administered alone or in combination with h[Gly2]-glucagon-like peptide 2. Am J Physiol 273:G1252-G1262, 1997
160. Fischer KD, Dhanvantari S, Drucker DJ, Brubaker PL: Intestinal growth is
161. Orskov C, Holst JJ, Knuhtsen S, Baldissera FGA, Poulsen SS, Nielsen OV: Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119:1467-1475, 1986
162. Orskov C, Holst JJ: Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47:165-174, 1987
163. Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai C-H, Drucker DJ: Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide 2. Endocrinology 138:4837-4843, 1997
164. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, Deforest L, Cooper S, Brubaker PL: Regulation of the biological activity of glucagon-like peptide 2 by dipeptidyl peptidase IV. Nat Biotechnol 15:673-677, 1997
165. Cheeseman CI, Tsang R: The effect of gastric inhibitory polypeptide and glucagon-like peptides on intestinal hexose transport. Am J Physiol 271:G477-G482, 1996
166. Brubaker PL, Izzo A, Hill M, Drucker DJ: Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 272:E1050-E1058, 1997
167. Chance WT, Foley-Nelson T, Thomas I, Balasubramaniam A: Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol 273:G559-G563, 1997